SCHEMBL31179155

SCHEMBL31179155

COC(=O)CN(C(=O)OC(C)(C)C)C(=O)c1cccc2c1cnn2C1CCCCO1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 1/20 0.38
▸ RXRB P28702 1/20 0.38
▸ RXRG P48443 1/20 0.38
▸ CYP11B2 P19099 1/20 0.35
▸ KRAS P01116 1/20 0.33
▸ CYP4F2 P78329 2/20 0.33
▸ CYP4A11 Q02928 2/20 0.33
▸ EP300 Q09472 1/20 0.33
▸ CREBBP Q92793 1/20 0.33
▸ ATR Q13535 6/20 0.32
▸ HTR2C P28335 2/20 0.32
▸ SLC6A4 P31645 2/20 0.32
▸ HTR4 Q13639 2/20 0.32
▸ EGFR P00533 1/20 0.30
▸ BTK Q06187 1/20 0.30
▸ CPB2 Q96IY4 1/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31179136 0.80 RXRA (0.41) RXRARXRBRXRGCYP11B2CYP4F2
SCHEMBL31178753 0.80 RXRA (0.42) RXRARXRBRXRGCYP11B2CYP4F2
SCHEMBL22941293 0.78 CYP11B2 (0.48) RXRARXRBRXRGCYP11B2CYP4F2
SCHEMBL31178830 0.77 CYP11B2 (0.35) RXRARXRBRXRGCYP11B2CYP4F2
SCHEMBL20116867 0.75 NQO2 (0.46) RXRARXRBRXRGATRMEN1
SCHEMBL22499127 0.75 RXRA (0.47) RXRARXRBRXRGCYP11B2CYP4F2
SCHEMBL22499128 0.75 RXRA (0.47) RXRARXRBRXRGCYP11B2CYP4F2
SCHEMBL31179070 0.75 RXRA (0.47) RXRARXRBRXRGCYP11B2CYP4F2
SCHEMBL19502544 0.74 RXRA (0.41) RXRARXRBRXRGCYP11B2CYP4F2
SCHEMBL22499231 0.74 RXRA (0.45) RXRARXRBRXRGCYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062412-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY CHUGAI PHARMACEUTICAL CO LTD (JP) 2026-03-05 — — US disclosed
EP-4647424-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-11-12 — — EP disclosed
WO-2024181437-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY 中外製薬株式会社 2024-09-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062412-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY MYT1, NTMT1, MYL6 RXRA 4502/4885RXRB 4401/4885RXRG 4358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback